Takeda Oncology
Andrew Ferguson, CA-AM, PhD, currently serves as the Director of Global Oncology R&D Alliance Management at Takeda Oncology, where responsibility includes leading discovery and clinical development alliances while ensuring alignment with business and scientific goals. Previously, Andrew held the position of Director of Portfolio & Alliance Management at X-Chem, Inc., managing strategic alliances with pharmaceutical and biotech companies. Earlier career highlights include roles as a Principal Scientist II at AstraZeneca, where Andrew directed scientific projects and alliance management, and as an Associate Principal Scientist at both Schering-Plough Research Institute and Merck, contributing to drug discovery and structural biology efforts. Andrew began an academic career as a Postdoctoral Fellow at UT Southwestern Medical Center, following the completion of a PhD in Microbiology and Immunology from McGill University and a Graduate Certificate in Biopharmaceutical Leadership from Emmanuel College.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.